Chemomab Therapeutics (CMMB) Other Gross PP&E Adjustments (2019 - 2025)
Chemomab Therapeutics posted quarterly Other Gross PP&E Adjustments of $487000.0 for Q4 2025, up 102.92% year-on-year from $240000.0 in Q4 2024, and up 284.47% on a QoQ basis from -$264000.0 in Q1 2025.
Chemomab Therapeutics (CMMB) has 7 years of Other Gross PP&E Adjustments data on file, last reported at $487000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 102.92% year-over-year to $487000.0; the trailing twelve-month figure through Dec 2025 stood at $487000.0 (up 102.92% YoY), and the FY2025 full-year result was $487000.0, up 102.92% from the prior year.
- Other Gross PP&E Adjustments for Q4 2025 stood at $487000.0, up from -$264000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $487000.0 in Q4 2025 and bottomed at -$397000.0 in Q1 2021.
- The 5-year median for Other Gross PP&E Adjustments is -$262500.0 (2022), against an average of -$138611.1.
- The widest annual swing landed in 2021, when Other Gross PP&E Adjustments jumped 158.62%; it then sank 142.31% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $119000.0 in 2021, then jumped by 156.3% to $305000.0 in 2022, then sank by 55.08% to $137000.0 in 2023, then surged by 75.18% to $240000.0 in 2024, then soared by 102.92% to $487000.0 in 2025.
- The last three Other Gross PP&E Adjustments figures came in at $487000.0 (Q4 2025), -$264000.0 (Q1 2025), and $240000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | 487,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 487,000.00 |
| Dec 31, 2025 | 487,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Dec 31, 2024 | 240,000.00 |
| Dec 31, 2024 | 240,000.00 |
| Sep 30, 2024 | -315,000.00 |
| Sep 30, 2024 | -315,000.00 |
| Jun 30, 2024 | -341,000.00 |
| Jun 30, 2024 | -341,000.00 |
| Mar 31, 2024 | -367,000.00 |
| Mar 31, 2024 | -367,000.00 |
| Dec 31, 2023 | 137,000.00 |
| Dec 31, 2023 | 137,000.00 |
| Sep 30, 2023 | -130,000.00 |
| Sep 30, 2023 | -130,000.00 |
| Jun 30, 2023 | -160,000.00 |
| Jun 30, 2023 | -160,000.00 |
| Mar 31, 2023 | -193,000.00 |
| Mar 31, 2023 | -193,000.00 |
| Dec 31, 2022 | 305,000.00 |
| Dec 31, 2022 | 305,000.00 |
| Sep 30, 2022 | -261,000.00 |
| Sep 30, 2022 | -261,000.00 |
| Jun 30, 2022 | -295,000.00 |
| Jun 30, 2022 | -295,000.00 |
| Mar 31, 2022 | -309,000.00 |
| Mar 31, 2022 | -309,000.00 |
| Dec 31, 2021 | 119,000.00 |
| Dec 31, 2021 | 119,000.00 |
| Sep 30, 2021 | -359,000.00 |
| Sep 30, 2021 | -359,000.00 |
| Jun 30, 2021 | -392,000.00 |
| Jun 30, 2021 | -392,000.00 |
| Mar 31, 2021 | -397,000.00 |
| Mar 31, 2021 | -397,000.00 |
| Dec 31, 2020 | -203,000.00 |
| Dec 31, 2020 | -203,000.00 |
| Sep 30, 2020 | -234,000.00 |
| Sep 30, 2020 | -234,000.00 |
| Jun 30, 2020 | -275,000.00 |
| Jun 30, 2020 | -275,000.00 |
| Mar 31, 2020 | -339,000.00 |
| Mar 31, 2020 | -339,000.00 |
| Dec 31, 2019 | -1.20 Mn |
| Dec 31, 2019 | -1.20 Mn |
| Sep 30, 2019 | -1.57 Mn |
| Sep 30, 2019 | -1.57 Mn |
| Jun 30, 2019 | -1.60 Mn |
| Jun 30, 2019 | -1.60 Mn |